Concepedia

Publication | Open Access

Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy

DOIFull Paper Access

39

Citations

56

References

2020

Year

Matthew B. Lipner, Xianlu L. Peng, Chong Jin, Yi Xu, Yanzhe Gao, Michael P. East, Naim U. Rashid, Richard A. Moffitt, Silvia G. Herrera Loeza, Ashley B. Morrison,
JCI Insight

Abstract

prescribed chemotherapeutic agent gemcitabine (GEM) Current guidelines recommend FOLFOX as an option for patients with GEM refractory PDAC (8).

References

YearCitations

Page 1